Αποτελέσματα Αναζήτησης
28 Αυγ 2023 · As a result, treatment of these conditions is difficult, incomplete, and not curative. (See "Risk factors for and possible causes of systemic sclerosis (scleroderma)" and "Pathogenesis of systemic sclerosis (scleroderma)" .) An overview of the management of adults with SSc will be discussed here.
9 Ιαν 2023 · The five-year survival rate (that is, patients who are still alive 5 years following diagnosis) among patients with diffuse cutaneous systemic sclerosis is about 84%. Five-year survival among patients with limited skin (cutaneous) systemic sclerosis is high — over 90%.
5 Απρ 2024 · Introduction. Systemic sclerosis, also known as scleroderma, is a rare connective tissue disorder with an unknown and complex pathogenesis. Scleroderma can be divided into 2 primary forms—localized scleroderma (including morphea, linear scleroderma, and scleroderma en coup de sabre) and systemic sclerosis.
Key points. •. Systemic sclerosis (SSc) has an estimated annual incidence of between 0.6 and 5.6 per 100,000 adults, with a high female predominance. •. SSc has one of the highest mortality rates of any rheumatic disease; however, the survival rate has improved with earlier detection and management of internal organ involvement.
14 Μαρ 2023 · It provides a roadmap for best practice management to try and harmonize treatment and investigation of SSc and defines key quality and audit standards that can be used to assess practice and improve outcomes.
Systemic sclerosis (SSc) has an estimated annual incidence of between 0.6 and 5.6 per 100,000 adults, with a high female predominance. SSc has one of the highest mortality rates of any rheumatic disease; however, the survival rate has improved with earlier detection and management of internal organ involvement.
Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults
